Innovative Immunology Biotech Windward Bio Lists on Nasdaq
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Windward Bio (Nasdaq: WWB) listed on Nasdaq on November 13, 2026, with an IPO priced at $17.00 per share. Shares closed their first trading day at $28.50, up 68% from the IPO price, valuing the company at approximately $1.69 billion. Qiming Venture Partners participated in the IPO after investing in earlier financing rounds.
Lead antibody program WIN378 is being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in chronic obstructive pulmonary disease. Windward holds exclusive global rights to WIN378, excluding Greater China and certain Asian countries, through licenses from Kelun-Biotech and Harbour BioMed. Its pipeline also includes clinical-stage WIN027, licensed from Qyuns Therapeutics.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNasdaq listing completed on November 13, 2026, with the IPO priced at $17.00 per share.
- Minor pointFirst-day shares closed at $28.50, up 68% from the IPO price; market capitalization reached approximately $1.69 billion.
- Minor pointWIN378 is in Phase 2/3 POLARIS-1 for severe uncontrolled asthma.
- Minor pointWIN378 is also being evaluated in Phase 2 SIRIUS for chronic obstructive pulmonary disease.
- Minor pointLicensed pipeline includes clinical-stage WIN027, an antibody targeting TSLP and IL-13.
- Minor pointQiming Venture Partners participated in the IPO financing after supporting Series A and Series B rounds.
Negative
- Minor pointWIN378 license rights exclude Greater China and certain Asian countries, limiting Windward's licensed territory.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Qiming Venture Partners invested in Windward Bio's inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026. Qiming also participated in this IPO financing round.
Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways. Led by a team with extensive expertise across discovery, development, and commercialization, Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines to improve clinical outcomes, reduce treatment burden and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.
Windward Bio's lead program, WIN378, is a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. WIN378 is currently being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in COPD. The company's pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases. Windward Bio holds exclusive global rights (excluding
"Qiming Venture Partners invests in differentiated, globally competitive biotech innovation designed to address significant unmet needs for patients, and Windward Bio exemplifies this approach. We believe novel, long-acting biologics will reshape the treatment of severe chronic respiratory and skin diseases, and that WIN378 and WIN027 have the potential to expand and meaningfully improve the treatment options available to patients. In the hands of Luca and his team, with their expertise and proven track record, Windward is well-positioned to deliver on this potential, and we look forward to supporting the company through its next phase of growth," said Alexander Sinclair Wilson, Principal at Qiming Venture Partners.
About Qiming Venture Partners
Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with
Since our debut, we have backed over 630 fast-growing and innovative companies. Over 290 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 110 portfolio companies that have achieved unicorn or super unicorn status.
Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.AI, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.
View original content:https://www.prnewswire.com/news-releases/innovative-immunology-biotech-windward-bio-lists-on-nasdaq-302939481.html
SOURCE Qiming Venture Partners
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was Windward Bio's IPO price and first-day closing price?
Windward Bio priced its IPO at $17.00 per share and closed its first trading day at $28.50, up 68%. Its market capitalization was approximately $1.69 billion.
Which clinical trials are evaluating Windward Bio's WIN378?
WIN378 is being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in chronic obstructive pulmonary disease.